Trial · NCT05612581
Outcomes23
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | STRIVE and THRIVE: Proportion of Participants Achieving Suppression of HBV DNA (< LLOQ) With HBsAg Loss (< 0.05 IU/mL) at the End of Treatment | Up to 48 weeks | Cohort 1a, 2a, 3a,5a and 1b was not opened for enrollment | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | STRIVE and THRIVE: Proportion of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Up to 96 weeks | |||
| SECONDARY | STRIVE and THRIVE: Proportion of Participants With Serum HBsAg ≤ 10 IU/mL at End of Treatment | Up to 48 weeks | |||
| SECONDARY | STRIVE and THRIVE: Proportion of Participants With Serum HBsAg ≤ 10 IU/mL at 24 Weeks Post-end of Treatment | Up to 72 weeks | |||
| SECONDARY | STRIVE and THRIVE: Serum HBsAg Levels and Change From Baseline Across Timepoints in the Study | Up to 96 weeks | |||
| SECONDARY | STRIVE and THRIVE: Serum HBsAg Level at Nadir During the Study | Up to 96 weeks | |||
| SECONDARY | STRIVE and THRIVE: Time to Achieve Nadir of Serum HBsAg During the Study | Up to 96 weeks | |||
| SECONDARY | STRIVE and THRIVE: Time to Achieve Serum HBsAg Loss (< 0.05 IU/mL) | Up to 96 weeks | |||
| SECONDARY | STRIVE and THRIVE: Proportion of Participants With HBsAg Loss With Anti-HBs Seroconversion at End of Treatment and at 24 Weeks Post-end of Treatment | Up to 76 weeks | |||
| SECONDARY | STRIVE: Proportion of Participants Achieving Sustained Suppression of HBV DNA (< LLOQ) With HBsAg Loss (< 0.05 IU/mL) After Discontinuation of All Treatment at 24 Weeks and at the F48 Follow-Up Visit | Up to 96 weeks | |||
| SECONDARY | STRIVE: Proportion of Participants With HBsAg Loss (<0.05 IU/mL) at End of Treatment and at 24 Weeks Post-end of Treatment | Up to 72 weeks | |||
| SECONDARY | STRIVE: Proportion of Participants Achieving Sustained Suppression of HBV DNA (< LLOQ) After Discontinuation of All Treatment at 24 Weeks and at the F48 Follow-Up Visit | Up to 96 weeks | |||
| SECONDARY | STRIVE: For HBeAg-positive Participants: Proportion of Participants With HBeAg Loss (Undetectable HBeAg) and/or Anti-HBe Seroconversion | Up to 72 weeks | |||
| SECONDARY | STRIVE: Incidence and Titers of Anti-drug Antibodies (ADA; if Applicable) to VIR-3434 | Up to 96 weeks | |||
| SECONDARY | STRIVE: Mean Change in Serum HBsAg Level From Baseline Across Timepoints in the Study | Up to 96 weeks | |||
| SECONDARY | STRIVE: Proportion of Participants Achieving HBV DNA (< LLOQ) Across Timepoints in the Study | Up to 96 weeks | |||
| SECONDARY | STRIVE: Proportion of Participants Achieving ALT ≤ ULN Across Timepoints in the Study | Up to 96 weeks | |||
| SECONDARY | THRIVE: Proportion of Participants Achieving Sustained Suppression of HBV DNA (< LLOQ) With HBsAg Loss (< 0.05 IU/mL) After Discontinuation of All Treatment at 24 Weeks and at 48 Weeks | Up to 92 weeks | |||
| SECONDARY | THRIVE: Proportion of Participants Achieving HBsAg Loss (< 0.05 IU/mL) at End of Treatment and at 24 Weeks Post-end of Treatment | Up to 44 weeks | |||
| SECONDARY | THRIVE: Proportion of Participants Achieving Sustained Suppression of HBV DNA (< LLOQ) After Discontinuation of All Treatment at 24 Weeks and at 48 Weeks | Up to 68 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05612581/outcomes